Trade Abbott Laboratories - ABT CFD

Abbott Company profile

What is Abbott Laboratories?

Abbott Laboratories is a US healthcare company that employs around 99,000 people and delivers its services in over 150 countries worldwide. Abbott produces and distributes a range of products under such popular brands as PediaSure, Glucerna, Similac, Absorb and others. Its mission statement is: “To improve lives by providing cost-effective health care products and services.”

The company focuses on the following healthcare segments: Nutrition, Vascular Care, Diabetes Care, Vision, Pharmaceuticals and Diagnostics. It advocates for innovation in medicine and works to improve vision correction, take heart health treatments to the next level and introduce innovative methods of diabetes management. 

Abbott has also pioneered new ways to screen, diagnose and monitor a wide range of health conditions with greater speed and accuracy. In pharmaceuticals, the company has revolutionised packaging and delivery to meet regional needs and offer access to medicines in areas that once lacked them.

Who are the key people at Abbott Laboratories?

Miles D. White is Chairman and Chief Executive Officer of Abbott. He has held both roles since 1999, and first joined the company back in 1984. Another key figure at Abbott Laboratories is Brian Blaser, Executive Vice President, Diagnostics Products. He leads Abbott's diagnostics, molecular and point-of-care businesses. Robert Ford is Executive Vice President, Medical Devices. 

What is the modern history of Abbott Laboratories?

Abbott was incorporated in 1894, and its initial public offering took place in 1929. Among a number of landmark developments in the second half of the 20th century was the acquisition of M&R Dietetics in 1964, which made the company a leader in nutrition. Abbott’s modern diagnostics business took off in the early 1970s, and in 1985 the FDA approved the firm’s test to identify HIV in blood. In 1998 Abbott introduced Glucerna – a range of snack bars and shakes for diabetics. The first decade of the 21st century saw FDA approval of antibody drug Humira, which became the world’s leading pharmaceutical product.

What are the latest developments at Abbott Laboratories?

In January 2017 Abbott completed the acquisition of St Jude Medical – a development which put the company in a leading position in the medical devices sector. Abbott now holds the No.1 or No.2 positions in nearly every segment of the $30 billion cardiovascular market. In 2017 Abbott also recorded 40 per cent growth in its neuromodulation business, attaining the No.1 spot in spinal cord neurostimulation.

In February 2018, Abbott announced a licensing deal with mid-tech firm Surmodics Inc that could be worth up to $92 million. Under the agreement, Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott. Surmodics is testing it as a treatment for peripheral artery disease.

Since the start of 2015, the Abbott share price has ranged from a low of around $37 in February 2016 to over $60 in January 2018. The company’s market capitalisation on 2 March 2018 was $103.5 billion. Our ABT chart tracks Abbott’s recent share price movements.

Where does Abbott Laboratories operate?

Abbott is headquartered in Chicago, Illinois. It has a truly global presence, with operations across the Americas, Europe and Asia Pacific – including China, India, Japan, Australia and New Zealand.

Where is Abbott Laboratories traded?

Abbott Laboratories is listed on the New York Stock Exchange. As of 2017, the shares were mainly held by institutional investors such as BlackRock, State Street Corporation and The Vanguard Group. Check out Capital.com for the latest ABT chart.

Latest shares articles

ECB Preview: no doubt about a cut, but 25 and 50 are both valid.
The European Central Bank is expected to cut rates on Thursday, but 25 or 50 basis points remains debatable.
14:05, 10 December 2024
US CPI the final hurdle before December FOMC decision
US CPI data on December 11 will influence the Fed's December rate cut decision. Analysts predict a 2.7% CPI rise, with sticky inflation in services complicating the path to the 2% target. Market focus remains on core inflation and its impact on 2025 rate expectations.
08:40, 10 December 2024
Market Analysis: stocks unbothered by politics ahead of US CPI
Global stocks remain at all-time highs despite several political events as investors focus on the US CPI data.
17:47, 9 December 2024
The RBA expected to keep policy unchanged at its December meeting
The RBA is set to meet for the final time in 2024, with the central bank handing down its decision at 2:30PM on Tuesday the 10th of December.
10:48, 6 December 2024

Read our reviews to find out more about us

Read the feedback from our clients around the world.
2024-10-22
infoaamon

Very trustworthy and affordable for any size trades

2024-10-21
remi74

It is very easy to connect with TradingView but the web interface is also great.

2024-10-15
jdancer37

Easy to use and great support. Been using it for 2 years already and still happy

2024-10-14
DANIEL

Capital.com is one of the best stock trading platforms I’ve used. The UX and UI on both the mobile app and web platform are outstanding, making it incredibly easy to navigate. They’ve built a vibrant community of traders and investors, and their UAE team really stands out for delivering an exceptional trading experience.

2024-10-08
Yahyaamez

Best broker!! they call you to see if you need any help. The app is good and nice better than the rest

2024-10-04
Iuliia Salivon

Great app! I requested some features to be added, such as analysis tools, and they delivered. Amazing job! The agents are always helpful and reply quickly. It’s not 5 stars because, at times, some less experienced agents may say it’s impossible to fulfill the request or fix the problem while another agent, like Angel, quickly escalated the issue to the necessary team/person/department and resolved it

2024-10-04
Moh ST

This is an excellent platform. The stop loss and take profit work very well; however, when the changes are very fast like at the beginning of the session, the stop loss does not work. If this defect is corrected it will be the perfect platform.

2024-09-30
adenysenko24

-Nice -Easy to use - Beautiful Interface

2024-09-26
Daniel

I think I'm new in this trading platform, but I find it affordable and most reliable. To be honest I'm not fully experienced trader, but with very limited knowledge of trading I try learn as much as I can by trying out different platforms see if can make money. My interests growing in you platform, l like news updates you also short videos on YouTube, other propaganda, poster and many more. I will see what happens in the coming months. Thanks capital team.

2024-09-26
John Fallows

Gives you options to start learning how too do it as it gives you a demo option to learn from your mistakes

2024-09-24
PHEMELO

Efficiency. When creating the account, it was smooth, efficient from start to finish. Verification of documents also was done the same day, unlike other platforms where you have to wait a day or two.

2024-09-04
Osondu Paul

From what I'm seeing it's cool Mixing it with trading view it's perfect... I didn't give it 5 star yet cos I still need to use it for some time

Showing our 4 & 5 star reviews

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading